Glenmark Pharmaceuticals Q1 Results with Revenue ₹23,295.37 Crore Profit Before Tax ₹6,183.14 Crore

Glenmark Pharmaceuticals Q1 Results

Glenmark Pharmaceuticals reported its financial results for the first quarter of 2024-2025. The company's revenue from operations was ₹23,295.37 crore, which is an increase from ₹21,443.84 crore in the same quarter last year. This shows a positive growth in sales and other operating income. The company also earned ₹556.48 crore in other income, bringing the total income to ₹23,851.85 crore.

Expenses for the quarter were ₹17,668.71 crore, slightly lower than ₹17,700.74 crore from the previous year. The major expenses included costs for materials, employee benefits, and finance costs. Glenmark’s profit before tax from continuing operations was ₹6,183.14 crore, a significant increase from ₹3,920.42 crore last year.

After accounting for taxes and exceptional items, the profit after tax for continuing operations was ₹4,537.31 crore, compared to ₹2,716.56 crore in the same quarter last year. The company's total comprehensive income, including adjustments for other comprehensive income, was ₹4,529.16 crore.

Source: Here 

For More Q1 Results check our Twitter Page 

Glenmark Pharmaceuticals Q1 Results 2024-2025 Overview

Glenmark Pharmaceuticals showed strong financial results in the first quarter of the fiscal year 2024-2025. They earned ₹23,295.37 crore from its core business, which is higher than the previous year. When adding other income, the total income was ₹23,851.85 crore. 

This financial report highlights Glenmark’s strong performance in the first quarter, showing increased revenues and profits.

Glenmark Pharmaceuticals Financial Metrics 

Glenmark Pharmaceuticals is a company with a market value of ₹44,124 Crores, which means it's worth a lot in the stock market. The current stock price is ₹1,564. The highest price it reached was ₹1,640, and the lowest was ₹702. 

Here's the stock information in table format:

Quarterly Results 

Glenmark Pharmaceuticals shows financial performance from December 2023 to June 2024. In December 2023, the company had lower sales and a negative operating profit, meaning it spent more than it earned. By March 2024, sales increased, and the company started making a profit on its core operations, with a significant improvement in profit margin. 

Here’s a summary of the financial metrics from December 2023 to June 2024:

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a global company that focuses on creating new medicines. They work in three main areas: respiratory issues, skin conditions, and cancer treatments. Glenmark makes a variety of products, including branded drugs, generic drugs, and over-the-counter (OTC) medicines.

Glenmark Pharmaceuticals has four research centers and ten top-quality manufacturing plants located in five different continents. Glenmark operates in more than eighty countries around the world. They are dedicated to being one of the first Indian companies to develop innovative drugs for global use.

Glenmark Pharmaceuticals is pursuing two main goals. The first goal is to discover completely new drugs, either chemical or biological. The second goal is to create special products that address unmet treatment needs.